Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic SclerosisTEL AVIV, Israel, ...
This trial was the first major clinical validation of the dual anti-inflammatory and anti-fibrotic mechanism of nebokitug. In patients with PSC, nebokitug reduced fibro-inflammatory biomarkers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback